Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Archemix and Lilly in Aptamer deal

This article was originally published in Scrip

Executive Summary

Archemix and Lilly are to explore the development of new aptamer-based drugs. The US biotechnology company will license certain IP rights from Lilly, which in return has an option to evaluate aptamers for certain drug targets. Lilly retains an option to enter into an exclusive licence with Archemix for up to two of the aptamer targets. No financial details were disclosed. Aptamers are synthetically derived oligonucleotides (short nucleic acid sequences) that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action.

You may also be interested in...



Innovation not M&A to drive Bayer growth in LatAm

Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.

2010 Scrip 100 - Is Anvisa a friend of innovators?

A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.

Elan raises $1.5 billion

Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel